Clinical Trials | December 24, 2025
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Adverse events were consistent with valbenazine’s established safety profile
Adverse events were consistent with valbenazine’s established safety profile
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Subscribe To Our Newsletter & Stay Updated
